Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma. . Eur J Haematol 2022 Apr 27. doi: 10.1111/ejh.13776.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma. Eur J Haematol 2022 Apr 27. doi: 10.1111/ejh.13776.
PMID: 35475526